C-myc is required for osteoclast differentiation

Journal of Bone and Mineral Research

Volumn 17, Issue 5, 2002, Pages 763-773

  Battaglino, R ^a   Kim, D ^a   Fu, J ^a   Vaage, B ^a   Fu, X Y ^b   Stashenko, P ^a  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone formation; Myc; Osteoclast differentiation

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CATHEPSIN K; GENE PRODUCT; MAX PROTEIN; MESSENGER RNA; MYC PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN MAD; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CONTROLLED STUDY; GENE EXPRESSION; GENE IDENTIFICATION; MONOCYTE; NONHUMAN; NORTHERN BLOTTING; ONCOGENE C MYC; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL; TISSUE SLICE;

ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; CARRIER PROTEINS; CELL DIFFERENTIATION; CELL LINE; DNA-BINDING PROTEINS; GENE EXPRESSION; GENES, MYC; MEMBRANE GLYCOPROTEINS; MICE; MONOCYTES; OSTEOCLASTS; OSTEOGENESIS; PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; REPRESSOR PROTEINS; TNF RECEPTOR-ASSOCIATED FACTOR 6; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 0036233577     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2002.17.5.763     Document Type: Article

References (56)

1. Stromal cell-mediated stimulation of osteoclastogenesis
2. Control of osteoclast differentiation
3. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors
4. Commitment and differentiation of stem cells to the osteoclast lineage
5. The MYC dualism in growth and death
6. Function of the c-Myc oncogenic transcription factor
7. The myc/MAX/MAD network and the transcriptional control of cell behavior
8. Functional role for c-myc in mitogenic response to platelet-derived growth factor
9. IL-2 and EGF receptors stimulate the hematopoietic cell cycle via different signaling pathways: Demonstration of a novel role for c-myc
10. Signal transduction by the high-affinity GM-CSF receptor: Two distinct cytoplasmic regions of the common beta subunit responsible for different signaling
11. Control of c-myc regulation in normal and neoplastic cells
12. Potentiation of growth factor activity by exogenous c-myc expression
13. Regulation of cell cycle duration by c-myc levels
14. c-Myc enhances protein synthesis and cell size during B lymphocyte development
15. c-Myc promotes differentiation of human epidermal stem cells
16. Normal and c-Myc-promoted human keratinocyte differentiation both occur via a novel cell cycle involving cellular growth and endoreplication
17. Structural characteristics of CD40 ligand that determine biological function
18. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
19. TRAF6 is a signal transducer for interleukin-1
20. Interferon-gamma has dual potentials in inhibiting or promoting cell proliferation
21. Dominant negative MYC blocks transformation by ABL oncogenes
22. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling
23. NF-kappa B-inducing kinase is a common mediator of IL-17-, TNF-alpha-, and IL-1 beta-induced chemokine promoter activation in intestinal epithelial cells
24. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily
25. The human toll signaling pathway: Divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6)
26. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2
27. The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor
28. Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif
29. Role of Rel-related factors in control of c-myc gene transcription in receptor-mediated apoptosis of the murine B cell WEHI 231 line
30. Protease inhibitors protect macrophages from lipopolysaccharide-induced cytotoxicity: Possible role for NF-kappaB
31. The suppression of T cell function and NF(kappa)B expression by serine protease inhibitors is blocked by N-acetylcysteine
32. Generation of mouse osteoclastogenic cell lines immortalized with SV40 large T antigen
33. A new cytokine-dependent monoblastic cell line with t(9;11)(p22;q23) differentiates to macrophages with macrophage colony-stimulating factor (M-CSF) and to osteoclast-like cells with M-CSF and interleukin-4
34. Expression of Src family kinases and their putative substrates in the human preosteoclastic cell line FLG 29.1
35. Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts
36. Role of 1 alpha, 25-dihydroxyvitamin D3 in osteoclast differentiation and function
37. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: Receptor activator of NF-kappa B ligand
38. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function
39. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families
40. Human osteoclasts derive from CD14-positive monocytes
41. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts
42. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression
43. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse
44. c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling
45. Requirement for NF-kappaB in osteoclast and B-cell development
46. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
47. Expression of vacuolar H(+)-ATPase in mouse osteoclasts during in vitro differentiation
48. Molecular cloning and characterization of a putative novel human osteoclast-specific 116-kDa vacuolar proton pump subunit
49. Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification
50. Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein
51. Induction of ornithine decarboxylase by IL-3 is mediated by sequential c-Myc-independent and c-Myc-dependent pathways
52. c-Myc induces apoptosis and cell cycle progression by separable, yet overlapping, pathways
53. Binding of NF-KB-like factors to regulatory sequences of the c-myc gene
54. Transactivation of the murine c-myc gene by HTLV-1 tax is mediated by NFkB
55. A novel NF-kappa B element within exon 1 of the murine c-myc gene
56. Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region